IQV:NYE-IQVIA Holdings Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 229.6

Change

0.00 (0.00)%

Market Cap

USD 42.82B

Volume

0.75M

Analyst Target

USD 184.17
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
TMO Thermo Fisher Scientific Inc

-9.43 (-1.67%)

USD 215.52B
DHR Danaher Corporation

-2.62 (-1.02%)

USD 188.85B
A Agilent Technologies Inc

-0.39 (-0.29%)

USD 39.30B
MTD Mettler-Toledo International I..

-27.18 (-1.87%)

USD 31.26B
LH Laboratory Corporation of Amer..

-0.16 (-0.08%)

USD 17.57B
WAT Waters Corporation

-2.30 (-0.80%)

USD 17.22B
DGX Quest Diagnostics Incorporated

-1.93 (-1.38%)

USD 15.31B
RVTY Revvity Inc.

-2.26 (-2.11%)

USD 13.32B
CRL Charles River Laboratories

-3.46 (-1.65%)

USD 10.90B
QGEN Qiagen NV

-0.99 (-2.36%)

USD 9.71B

ETFs Containing IQV

EKG First Trust Nasdaq Lux Di.. 6.96 % 0.00 %

+0.07 (+0.04%)

USD 2.38M
XYLU:LSE Global X S&P 500® Covere.. 4.73 % 0.00 %

-0.02 (0.04%)

USD 0.02B
XYLP:LSE Global X S&P 500® Covere.. 4.70 % 0.00 %

+0.01 (+0.04%)

USD 0.02B
BBH VanEck Biotech ETF 4.14 % 0.35 %

-0.26 (0.04%)

USD 0.43B
MID American Century Mid Cap .. 3.80 % 0.00 %

+0.04 (+0.04%)

USD 0.07B
IBB iShares Biotechnology ETF 3.78 % 0.47 %

-0.43 (0.04%)

USD 7.43B
VNMC Natixis ETF Trust II - Na.. 2.63 % 0.00 %

-0.15 (0.04%)

USD 4.19M
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.23 % 0.00 %

-0.06 (0.04%)

USD 0.05B
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.23 % 0.00 %

-0.05 (0.04%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.23 % 0.00 %

+0.01 (+0.04%)

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
PBI Pitney Bowes Inc 0.00 % 0.79 %

-0.09 (0.04%)

USD 0.85B
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

-0.05 (0.04%)

CAD 0.05B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

N/A

CAD 0.05B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.77% 38% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.77% 31% F 28% F
Trailing 12 Months  
Capital Gain 15.12% 85% B 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.12% 85% B 53% F
Trailing 5 Years  
Capital Gain 68.07% 55% F 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.07% 55% F 72% C
Average Annual (5 Year Horizon)  
Capital Gain 14.36% 62% D 78% C+
Dividend Return 14.36% 62% D 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.23% 62% D 38% F
Risk Adjusted Return 49.14% 62% D 71% C-
Market Capitalization 42.82B 77% C+ 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.